Sanofi, Johnson & Johnson, Eli Lilly and Bristol Myers Squibb have each filed complaints after facing federal opposition to ...

Sanofi has filed a lawsuit against the Biden administration over payment terms in a federal drug discount program.

The Health Resources and Services Administration last week directed Sanofi to cease implementation of its 340B rebate ...

The drugmaker is following in the footsteps of Johnson & Johnson and Eli Lilly in filing suit to force through controversial ...

Four drug manufacturers have announced plans to offer discounted drug prices to safety net providers under the federal 340B program via ...

HRSA warns Sanofi that its credit model for 340B drugs violates the statute, demanding immediate cessation to avoid penalties ...

The 340B program has become a flash point in the growing debate over the cost of prescription drugs in the U.S.

The claim was filed Monday, alleging the federal government lacks the authority to stop the company from implementing the proposed rebate model. Other news is on staffing shortages; health claim ...

Johnson & Johnson and other pharma companies aim to change how the 340B Drug Pricing Program functions. Courts must rule if ...

The Health Resources and Services Administration has issued a warning to Sanofi over its plan to implement a new credit model for sales of certain covered outpatient drugs, threatening to remove the ...

HRSA on Friday warned Sanofi against implementing its planned rebate model for some of its outpatient drugs under the drug ...